Optimising low-dose methotrexate for rheumatoid arthritis-A review

Catherine J. Lucas, Simon B. Dimmitt, Jennifer H. Martin

Research output: Contribution to journalReview articlepeer-review

16 Citations (Scopus)


Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intrapatient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this could help inform dosage regimens.

Original languageEnglish
Pages (from-to)2228-2234
Number of pages7
JournalBritish Journal of Clinical Pharmacology
Issue number10
Early online date9 Aug 2019
Publication statusPublished - 1 Oct 2019


Dive into the research topics of 'Optimising low-dose methotrexate for rheumatoid arthritis-A review'. Together they form a unique fingerprint.

Cite this